In cancer, CD103+ TRM tumor-infiltrating T lymphocytes (TILs) are known to be immunophenotypically diverse, ranging from terminally exhausted (layilin+), TRM precursors (granzyme H+) and TRM transitional-phase (XCL1+) cells11. This evidence concerns the gene ITGAE and neoplasm.